Compare Navitas Semiconductor Corporation Common Stock (NVTS) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navitas Semiconductor Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Navitas Semiconductor Corporation Common Stock trades at $8.96 (market cap $2.63B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 4× Navitas Semiconductor Corporation Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Navitas Semiconductor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Navitas Semiconductor Corporation Common Stock for 3 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NVTS | PCVX | |
|---|---|---|
Market Cap | $2.63B | $10.51B |
Volume | 20,633,069 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $31.79 | $73.82 |
52-Week Low | $7.14 | $40.32 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $2.07B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Navitas Semiconductor (NVTS) trades at $10.45, up 4.6% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with moving averages indicating selling pressure, but oscillators suggest some bullish momentum. Fundamentally, the company is in a growth investment phase, reporting negative net income margins and significant cash burn from operations, offset by strong financing inflows. Recent news highlights strategic collaborations with NVIDIA and Microchip for AI data center power solutions and a U.S. Army contract for silicon carbide chip development, positioning NVTS in high-growth power semiconductor markets.
The outlook for NVTS hinges on execution in the AI and defense power semiconductor segments, with a consensus price target of $16.65 implying substantial upside. However, high valuation multiples, persistent losses, and competitive intensity pose significant risks. Investors should weigh the company's promising market positioning against its current lack of profitability and the capital-intensive nature of its expansion.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Navitas Semiconductor Corporation Common Stock
Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.
Read more on NVTS →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
